Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles For Members Only Event-Driven Fund Posts Double-Digit Returns in Each of Its First Five Years Stephen Taub For Members Only CTAs Navigate Market Whiplash as Traditional Assets Struggle Stephen Taub From Informing AI to Empowering Traders, Quality Data is Non-Negotiable Sponsored by CME Group